RTsafe announces first use of its PseudoPatient patient-specific quality assurance process
News

RTsafe announces first use of its PseudoPatient patient-specific quality assurance process

Spain’s renowned centre of excellence recognises importance of verifying radiosurgery plans ahead of patient treatment

  • By IPP Bureau | March 15, 2023

RTsafe, the leading provider of quality assurance products and services in stereotactic radiosurgery, announces that Spain’s Fundación Instituto Valenciano de Oncología (IVO – www.ivo.es) has conducted its first simulated therapy for brain metastases using PseudoPatient, RTsafe’s patient-specific quality assurance process that comprises an anatomically faithful model of each patient’s head aligned to dosimetric evaluation services. The technology enables medical physicists and clinicians to verify the entire treatment process before the actual patient is subjected to radiotherapy.

Commenting on the announcement, Evangelos Pappas, Founder and Chief Scientific Officer at RTsafe said: “We are delighted that IVO, Spain’s internationally renowned centre of excellence in cancer treatment, has embraced the concept of assuring patient safety and treatment efficiency through human-like simulation of the stereotactic radiosurgery process.”

The simulation was carried out ahead of IVO’s first patient treatment using the new TrueBeam linear accelerator from Varian Medical Systems, a Siemens Healthineers company, that integrates radiotherapy and image-guided radiosurgery on the same platform. The machine was acquired as part of the ongoing efforts by IVO’s Radiation Oncology Service to increase patient safety and treatment quality.

A case study published by medical technology distribution company, Aplicaciones Tecnológicas de la Física, points out that due to the complexity of administering SRS plans, periodic quality control protocols and pre-treatment dose verification procedures based on the actual patient anatomy are advisable and could improve treatment efficiency.

Evangelos Pappas added: “Brain metastases can occur in more than 30% of all cancer patients and, while SRS is a good treatment option for many patients, its complexity means that accurate pre-treatment dose verification could make a difference to treatment outcomes should an adjustment to dosage or targeting be indicated by the simulation process. The approach improves the confidence of both medical professionals and patients in this exacting treatment method.”

Upcoming E-conference

Other Related stories

Startup

Digitization